Development of Potent and Selective PfCLK3 Inhibitors Based on GSK-TCMDC151 as a New Class of Antimalarials

doi 10.26434/chemrxiv.9817202.v1

Full Text

Abstract

Available in

Date

Authors

Publisher

American Chemical Society (ACS)


Related search